dihexa peptide cognitive enhancer is changing the conversation around optimization., This is one of PA Tammy’s many, many favorite peptides! And for good reason 😉, Unlike options that can leave you feeling jittery or DIHEXA - Beverly Hills Rejuvenation

Clinical data suggests that GIP co-activation with GLP-1 may also reduce nausea rates compared to GLP-1 stimulation alone, which could explain why Retatrutide and Tirzepatide cause less nausea than Semaglutide despite being more potent compounds

Blood (25 L) was collected from the retro-orbital sinus for up to 23 days

Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)

Declining estrogen and testosterone levels can lead to vaginal dryness, mood swings, sleep disturbances, and reduced sex drive